News | June 13, 2009

Lantheus to Receive LEU-derived Mo-99 from Australian Nuclear Science

June 13, 2009 - Lantheus will be the first company to be able to offer Technetium-99 (Tc99m) derived from LEU to the U.S. market.

The company says it is committed to ensuring reliable supply and global access to Tc99m, the medical isotope used in approximately 80 percent of all nuclear medicine procedures. Lantheus, together with ANSTO, is working closely with the FDA and Health Canada to achieve the necessary LEU Mo-99 approvals for the U.S. and Canadian markets.

Low enriched uranium (LEU) is a new and safer option for Mo-99 suppliers that cannot be used in nuclear weapons, therefore eliminating the risk of terrorism threats to LEU reactors.

Lantheus’ arrangement with ANSTO emphasizes Lantheus’ ongoing commitment to investing in a supply chain diversification
strategy and providing new solutions to addressing the limited and fragile global Mo-99 supply chain, as evidenced by the current
NRU reactor shutdown in Canada. Without adequate supply of Mo-99, crucial imaging tests that can diagnose life-threatening
conditions such as heart disease and cancer must be canceled or postponed. This arrangement marks another step in Lantheus’
supply chain diversification strategy. In May 2009, Lantheus signed an agreement with NTP Radioisotopes (Pty) Ltd., a subsidiary
of the South African Nuclear Energy Corporation (NECSA), to manufacture and supply Lantheus with an ongoing volume of
Mo-99.

With only a few global suppliers of Mo-99, aging reactors will continue to need more frequent maintenance and repairs. In addition, as the healthcare industry faces an aging population, and the demand for diagnostic services continues to rise, the need for a consistent, reliable supply of Mo-99 has become increasingly critical.

For more information: www.lantheus.com

Related Content

Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
Overlay Init